Tumor response assessment currently relies upon measurement of size change, which may not alter significantly early during treatment or at all with newer therapies. Patients may therefore incur significant side-effects (with associated healthcare cost) without benefit. Assessment of soft tissue tumor T1 relaxation times before and early during treatment can predict lesion response whilst being incorporated within a clinically feasible whole-body MRI scan duration. Tumors undergoing partial response at the end of treatment demonstrated significant reduction in T1 values early during therapy compared to non-responding lesions.
In the future, this could facilitate early response assessment and complement other imaging biomarkers.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords